Xiagem Trio 1 Tablet ER is a combination oral antidiabetic medication containing Glimepiride 1mg, Metformin 500mg, and Voglibose 0.2mg, formulated for extended release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, attenuating postprandial hyperglycemia. The combination of these agents targets multiple pathophysiological defects in type 2 diabetes, providing comprehensive glycemic management. Xiagem Trio 1 Tablet ER is indicated for patients inadequately controlled by diet and exercise alone or monotherapy, offering improved efficacy through complementary mechanisms of action. The extended-release formulation allows for once-daily dosing, enhancing patient compliance and maintaining steady plasma drug concentrations. It is essential to monitor blood glucose levels regularly and adjust therapy based on clinical response and tolerability. Caution is advised in patients with renal or hepatic impairment, and contraindications include type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to any component. Adverse effects may include hypoglycemia, gastrointestinal disturbances, and rare allergic reactions.